AimdR: AI Screening for Diabetic Retinopathy

Sponsor
West German Center of Diabetes and Health (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05704491
Collaborator
(none)
100
1
35
2.9

Study Details

Study Description

Brief Summary

The increasing prevalence of diabetes mellitus represents a major health problem, especially since around 40% of diabetic patients develop diabetic retinopathy, which severely impairs vision and can lead to blindness. This development could be prevented by annual check-ups and timely referral for treatment. However, there are major differences in the quality of examinations and bottlenecks in examination appointments. A solution to the problem could be the use of artificial intelligence (AI), especially deep learning. Initial studies have shown that deep learning algorithms can be used successfully to detect diabetic retinopathy. However, it remains to be clarified whether the use of AI can achieve a sufficiently high level of accuracy in the detection of retinopathies. Therefore, in the present study, the positive predictive value (PPV), the negative predictive value (NPV), the sensitivity (SEN) and the specificity (SPEZ) of the AI algorithm 'MONA-DR-Model' in the detection of diabetic retinopathy should be measured. In addition, it is to be examined how well the classification into mild and severe retinopathy corresponds and how well this new examination method is accepted by the patients.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: artificial intelligence (AI) algorithm of the MONA DR model

Detailed Description

As part of the study, a 45-degree fundus image is taken for each eye and patient using the 'Crystalvue NFC 600'. The fundus photographs are then analyzed using the 'MONA-DR-Mode'l and classified as "diabetic retinopathy according to AI present (K+)" or "diabetic retinopathy according to AI absent (K-)". These classifications are compared with the results ("diabetic retinopathy according to the doctor present (A+)" or "diabetic retinopathy according to the doctor absent (A-)") of the examinations routinely provided for in the Disease Management Program (DMP) diabetes mellitus type 2 by resident ophthalmologists who work in the period 6 months before and after the fundus photography in the West German Centre of Diabetes and Health (WDGZ) were compared. All patients with the assessment "diabetic retinopathy according to AI present (K+)" or discrepancies with the ophthalmological DMP examination in the outpatient environment are offered a routine appointment at the Marienhospital. There, an eye examination is then carried out by an ophthalmologist and, without knowledge of the previous findings, a reassessment and classification as "diabetic retinopathy according to the doctor present (A+)" or "diabetic retinopathy according to the doctor absent (A-)" is carried out by the AI.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Case-Control
Time Perspective:
Other
Official Title:
Accuracy of an AI Model for Diabetic Retinopathy Screening in Real-life
Anticipated Study Start Date :
Jan 30, 2023
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
K+A+

diabetic retinopathy according to AI present (K+) AND diabetic retinopathy according to the doctor present (A+)

Diagnostic Test: artificial intelligence (AI) algorithm of the MONA DR model
A 45-degree fundus image is taken for each eye and patient using the Crystalvue NFC 600. The fundus photographs are then analyzed using the MONA DR model and classified for presence of diabetic retinopathy.

K+A-

diabetic retinopathy according to AI present (K+) AND diabetic retinopathy according to the doctor absent (A-)

Diagnostic Test: artificial intelligence (AI) algorithm of the MONA DR model
A 45-degree fundus image is taken for each eye and patient using the Crystalvue NFC 600. The fundus photographs are then analyzed using the MONA DR model and classified for presence of diabetic retinopathy.

K-A+

diabetic retinopathy according to AI absent (K-) AND diabetic retinopathy according to the doctor present (A+)

Diagnostic Test: artificial intelligence (AI) algorithm of the MONA DR model
A 45-degree fundus image is taken for each eye and patient using the Crystalvue NFC 600. The fundus photographs are then analyzed using the MONA DR model and classified for presence of diabetic retinopathy.

K-A-

diabetic retinopathy according to AI absent (K-) AND diabetic retinopathy according to the doctor absent (A-)

Diagnostic Test: artificial intelligence (AI) algorithm of the MONA DR model
A 45-degree fundus image is taken for each eye and patient using the Crystalvue NFC 600. The fundus photographs are then analyzed using the MONA DR model and classified for presence of diabetic retinopathy.

Outcome Measures

Primary Outcome Measures

  1. PPV [12 months]

    positive predictive value

  2. NPV [12 months]

    negative predictive value

  3. SEN [12 months]

    sensitivity

  4. SPEZ [12 months]

    specificity

Secondary Outcome Measures

  1. patients preferences [12 months]

    questionnaire for patients preferences and satisfaction concerning the AI-supported eye examination

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of diabetes mellitus

  • Diabetes duration ≥ 5 years

  • Age > 18 years old

  • Patient is able to give informed consent

  • Fluent in written and spoken German, or interpreter present

Exclusion Criteria:
  • History of laser treatment

  • Contraindication to the fundus imaging systems used in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 West German Center of Diabetes and Health Düsseldorf Germany 40591

Sponsors and Collaborators

  • West German Center of Diabetes and Health

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
West German Center of Diabetes and Health
ClinicalTrials.gov Identifier:
NCT05704491
Other Study ID Numbers:
  • AimdR
First Posted:
Jan 30, 2023
Last Update Posted:
Jan 30, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 30, 2023